Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. - Wikidata - awgldk - TriplyDB

Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.

Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.

http://www.wikidata.org/entity/Q36255616

about

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Management of anaplastic thyroid cancer Combined MEK and Pi3'-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo.Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.The ninth International Conference of Anticancer Research, 6-10 October 2014, Sithonia, Greece.Development and characterization of six new human papillary thyroid carcinoma cell lines.Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.Modulation of sodium iodide symporter in thyroid cancer PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.Mouse models of thyroid cancer: A 2015 update.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer Modeling anaplastic thyroid carcinoma in the mouse.Overview of Genetically Engineered Mouse Models of Papillary and Anaplastic Thyroid Cancers: Enabling Translational Biology for Patient Care Improvement.Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.MicroRNAs in the thyroid.PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors.Structural alterations in tumor-draining lymph nodes before papillary thyroid carcinoma metastasis.Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene.Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model Mouse models of sporadic thyroid cancer derived from BRAFV600E alone or in combination with PTEN haploinsufficiency under physiologic TSH levels Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models

P2860

Q27026323-C844AF39-4D55-4DB4-8D34-8718D862D3D5 Q28080836-17035CF8-CA72-4CA8-A7AB-27C1ED75C895 Q33648582-A50E0F19-7D5D-4EEA-9142-B5AAF9CD4F3D Q34123525-0F0F22A9-635C-4312-AC80-46BB0CD42A8B Q34680642-A02AFB76-7A09-4627-95A5-4EE847BADB85 Q35055107-60548D7E-6827-41B4-AE0B-52CD2974E046 Q35234108-DD7D201F-09B0-48DE-A80A-59876530F6C9 Q35690173-C92F6AC0-ABC3-411E-AD5C-E04B4ADC387B Q36378189-69805EC2-520B-4118-96F5-2E62F30A8187 Q36405539-03D52B70-B253-4AA1-A524-C2E7E4D74D1F Q36618604-27800E7E-3A24-40AA-80BB-980CD7DF6147 Q37376300-5C028795-3B93-4C28-9F85-5D806942DBF6 Q37725293-8FE9FD33-CB70-4283-B660-3865FB52BBC1 Q38270915-8843FCD7-61C9-49E1-9B75-34C8BCD48B07 Q38581928-62A6CD46-E2D2-42AF-996C-465365B80827 Q38657760-269D51CF-9CE2-41EC-B500-E62C6F12D65D Q38873867-5B48C469-21F6-4BAD-A3A9-7FB6BB5DDB91 Q39030847-D508F732-223C-461D-B172-C39C54EC2CEB Q47142625-7504427C-4AF6-4AAE-9ECB-858B6E44B190 Q47149651-A5226FC3-9246-438A-A2CA-44E8FA0E005B Q48088782-F634FB56-860B-4E7F-8ED1-EA7510298911 Q52664598-7E726A2A-A203-4675-A9D5-6E2435CE024A Q52730006-A9A1643C-E09F-429B-9931-BEDDA7FA4788 Q52839686-BAACBD77-E399-4430-8057-054C5E89C395 Q55345025-DD7A7518-5E9C-44C8-B86F-0860158D81BE Q58701147-B878C2FF-5B54-4CE9-94FC-7462BFE073E3 Q58706948-42B3F708-B82D-4E0C-8B1D-05D27F9D6448 Q58797975-D2D4A267-8F76-4C24-A394-D10EE2908BC8 Q59129787-3C5E9DE9-6BE7-4C20-AE97-CCE7EA7F7A68

P2860

Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.

http://www.wikidata.org/entity/Q36255616

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Activating BRAF and PIK3CA mut ...... lastic thyroid carcinogenesis.

@ast

Activating BRAF and PIK3CA mut ...... lastic thyroid carcinogenesis.

@en

type

label

Activating BRAF and PIK3CA mut ...... lastic thyroid carcinogenesis.

@ast

Activating BRAF and PIK3CA mut ...... lastic thyroid carcinogenesis.

@en

prefLabel

Activating BRAF and PIK3CA mut ...... lastic thyroid carcinogenesis.

@ast

Activating BRAF and PIK3CA mut ...... lastic thyroid carcinogenesis.

@en

P1433

Q36255616-CE17B0A4-A205-4E94-979F-940E0D5C3343

P1476

Q36255616-E30EF5DF-EAD1-4295-A98F-A818AC1CC636

P2093

Q36255616-0D71C23E-73FC-4999-8E86-076F97A0E192

Q36255616-68028B86-1AC8-4848-BDE9-4EDA720BA450

Q36255616-F2511CB4-221C-44A2-BC16-5C8E03CC7965

P2860

Q36255616-0078E4C0-12CF-41FF-A972-C76C7B03E56F

Q36255616-03829E3C-C4A9-485F-BE70-69BAF10917FC

Q36255616-0A1C5FD0-501F-466D-9B3C-A9FE541BA254

Q36255616-1B8DD707-F60B-4AEC-9A50-19F7CF6257F6

Q36255616-2396F2C4-8F6F-4843-A2F1-1125FFAA884E

Q36255616-2D0A8068-971D-4C70-8394-69AC715B5F05

Q36255616-332BC7DE-2173-46B7-AF64-9C6337522FB6

Q36255616-3F44E677-ABC1-4F66-8CE9-DD97F13CAADB

Q36255616-44C43DAA-F924-4A29-AFF8-A7F41A0A4B89

Q36255616-66C39DFC-B3F3-495C-BB92-AB3AD6926CA4

P304

Q36255616-DDA09455-C2A5-4646-A4FD-59A0274FD377

P31

Q36255616-198ECE82-50ED-482B-A799-5ED6A1559757

P356

Q36255616-E914C81D-9EDD-44CA-8781-0667B04152A0

P433

Q36255616-0073F3AD-188A-4EF7-BDEA-67B42EA8B319

P478

Q36255616-BBCBB211-E189-4196-91DD-15F0D84682DD

P50

Q36255616-8107F778-9F74-4C1F-939F-C4B34B86A126

Q36255616-D8455F6B-ECF2-4DAE-8361-0156ED3CB9B9

P577

Q36255616-5E848DFA-B4BD-440C-A5A2-21FFB4DFB580

P5875

Q36255616-59C2A27B-EB91-4FDB-8519-48E0639BF4F3

P698

Q36255616-0C2A52FD-6D16-40FE-94BF-B0B7AA4D9E19

P932

Q36255616-241D444C-CC25-4B48-971F-9D0F0DC62D96

P356

1541-7786.MCR-14-0158-T

P1433

Molecular Cancer Research

P1476

Activating BRAF and PIK3CA mut ...... lastic thyroid carcinogenesis.

@en

P2093

Gioia Iezza

http://www.w3.org/2001/XMLSchema#string

Jillian Silva

http://www.w3.org/2001/XMLSchema#string

Martin McMahon

http://www.w3.org/2001/XMLSchema#string

P2860

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Mutations of the BRAF gene in human cancer

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.

P304

979-986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1541-7786.MCR-14-0158-T

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Wayne A. Phillips

Roch-Philippe Charles

P577

2014-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261922093

http://www.w3.org/2001/XMLSchema#string

P698

24770869

http://www.w3.org/2001/XMLSchema#string

P932

4635659

http://www.w3.org/2001/XMLSchema#string